

University of California
San Francisco



DEPARTMENT OF MEDICINE

Talmadge E. King, Jr., MD
Julius R. Krevans Distinguished
Professorship in Internal Medicine
Chair
Department of Medicine

505 Parnassus Avenue
San Francisco, CA 94143-0120
Phone: 415-476-0909
FAX: 415-502-5869
e-mail: tking@medicine.ucsf.edu

September 27, 2007

**TO: Department of Medicine PIs and Research Administration
Staff**

FROM: Talmadge E. King, Jr., MD

**RE: REVISED Policy on Commensurate Salary for Investigator
Initiated Clinical Trials**

The policy of the Department of Medicine is that all research on which faculty spend time should have that time appropriately allocated to the research project and paid by the funding agency. This policy applies to grants and contracts with governmental agencies, not-for-profit entities, and for-profit entities.

An issue has arisen regarding the granting by pharmaceutical companies of free drugs for investigative purposes or for compassionate use. These donations may be at the initiation of the pharmaceutical company or they may be investigator-initiated.

To be consistent with departmental policy, the following policies will hold for these situations:

If initiated by the pharmaceutical company

- If the provision of drug is at the initiation of the pharmaceutical company, an appropriate percentage of the faculty member's time should be designated and supported by the company in addition to the expense of providing the drug. The minimum percentage of effort and salary support should be no less than 3%.

If initiated by a UCSF investigator

- If the drug donation is investigator-initiated for compassionate clinical use, not in the context of research of any type, then the free drug can be accepted without any corresponding support for the faculty member's time.
- If the project is investigator-initiated and the patient will be in a clinical research study of any sort, the physician's time should be supported by one of the following:
 - a. the same company that supplies the medication, if the company seeks rights to certain aspects of the research (such as intellectual property rights)
 - b. discretionary funding from pharmaceutical sources (such as excess funding from other clinical trials)
 - c. gift fund that is specifically earmarked for clinical research. Proof of such must be documented in the award letter
 - d. government funding (such as an NIH grant) if the time spent is consistent with the faculty member's commitment under the specifications of the grant

Proposals from faculty members should clearly indicate into which category their proposal falls via the Chief to Chair letter that is required of every proposal.

Sincerely Yours,

Talmadge E. King, Jr. M.D.